drugset / Trial / NCT06824103

Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

NCT06824103

Phase 4 Recruiting 50 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the efficacy and safety of ruxolitinib in Chinese adult and pediatric participants aged 12 years or older with corticosteroid-refractory chronic graft vs. host disease (SR-cGvHD).

Timeline

Start
2025-09-09
Primary completion
2029-05-10
Completion
2031-05-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule 10 mg Oral